Published in Cancer Weekly, January 10th, 2006
The medical school has already conducted over 7,000 cancer treatments on its two existing BSD-2000s.
Improved treatment for these two cancers is a high priority, as rectal cancer is the second leading cause of death from cancer, with pancreatic cancer following as fourth. Expanding the use of the BSD-2000 for treatment of these cancers is expected to further demonstrate and broaden...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.